JP2012515217A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515217A5 JP2012515217A5 JP2011546347A JP2011546347A JP2012515217A5 JP 2012515217 A5 JP2012515217 A5 JP 2012515217A5 JP 2011546347 A JP2011546347 A JP 2011546347A JP 2011546347 A JP2011546347 A JP 2011546347A JP 2012515217 A5 JP2012515217 A5 JP 2012515217A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphoma
- administered
- combination
- cell
- ofatumumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 11
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 9
- 229960002707 bendamustine Drugs 0.000 claims 9
- 229960002450 ofatumumab Drugs 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 7
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 4
- 201000003444 follicular lymphoma Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 210000003519 mature b lymphocyte Anatomy 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 210000003826 marginal zone b cell Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 claims 1
- 210000001978 pro-t lymphocyte Anatomy 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14521009P | 2009-01-16 | 2009-01-16 | |
| US61/145,210 | 2009-01-16 | ||
| PCT/US2010/021123 WO2010083365A1 (en) | 2009-01-16 | 2010-01-15 | Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012515217A JP2012515217A (ja) | 2012-07-05 |
| JP2012515217A5 true JP2012515217A5 (https=) | 2013-03-07 |
Family
ID=42340093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011546347A Pending JP2012515217A (ja) | 2009-01-16 | 2010-01-15 | ベンダムスチンおよび抗−ｃｄ２０抗体の組合せを用いた癌治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110274697A1 (https=) |
| EP (1) | EP2405937A4 (https=) |
| JP (1) | JP2012515217A (https=) |
| KR (1) | KR20110111303A (https=) |
| CN (1) | CN102355907A (https=) |
| AU (1) | AU2010204666A1 (https=) |
| BR (1) | BRPI1006829A2 (https=) |
| CA (1) | CA2749151A1 (https=) |
| EA (1) | EA201170940A1 (https=) |
| IL (1) | IL213794A0 (https=) |
| MX (1) | MX2011007589A (https=) |
| SG (1) | SG172792A1 (https=) |
| WO (1) | WO2010083365A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI409079B (zh) * | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| KR20140064873A (ko) * | 2011-08-16 | 2014-05-28 | 모르포시스 아게 | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| FR2980110A1 (fr) * | 2011-09-20 | 2013-03-22 | Lfb Biotechnologies | Combinaison d'anticorps anti-cd20 et de bendamustine |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| US20190231757A1 (en) * | 2016-07-13 | 2019-08-01 | Takeda Pharmaceutical Company Limited | Combination of spleen tyrosine kinase inhibitors and other therapeutic agents |
| CN110540593B (zh) * | 2018-05-29 | 2022-05-17 | 上海药明生物技术有限公司 | 新型的抗cd3/抗cd20双特异性抗体 |
| EP3802622A4 (en) * | 2018-05-29 | 2021-08-18 | Wuxi Biologics Ireland Limited | NEW BISPECIFIC ANTI-CD3 / ANTI-CD20 ANTIBODY |
| KR20210078505A (ko) | 2018-10-16 | 2021-06-28 | 유에스 나노 푸드 앤 드럭 인코포레이티드 | 종양내 주사 제형 |
| WO2021211294A1 (en) * | 2020-04-13 | 2021-10-21 | US Nano Food & Drug INC | Basic chemotherapeutic intratumour injection formulation |
| CA3217391A1 (en) | 2020-07-27 | 2022-02-03 | Youwei ZHU | Formulation of novel bispecific anti-cd3/cd20 polypeptide complex |
| GB202218493D0 (en) * | 2022-12-08 | 2023-01-25 | Oncopeptides Ab | Novel therapeutic combinations |
| WO2024179545A1 (zh) * | 2023-03-01 | 2024-09-06 | 上海津曼特生物科技有限公司 | 包含cd20/cd47阻断双功能融合蛋白的联合用药物及其用途 |
| WO2024263801A2 (en) * | 2023-06-20 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating ovarian cancer |
| WO2024263804A2 (en) * | 2023-06-20 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating kidney cancer |
| WO2024263798A1 (en) * | 2023-06-20 | 2024-12-26 | Burzynski Stanislaw R | Compositions comprising antineoplastons and methods of treating prostate cancer |
| EP4731199A2 (en) * | 2023-06-21 | 2026-04-29 | Stanislaw R. Burzynski | Compositions comprising antineoplastons and methods of treating colorectal cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0315295C1 (pt) * | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| WO2005044307A2 (en) * | 2003-11-04 | 2005-05-19 | Chiron Corporation | Methods of therapy for b cell-related cancers |
| WO2007054719A2 (en) * | 2005-11-10 | 2007-05-18 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent |
| US9382327B2 (en) * | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| WO2009083009A2 (en) * | 2008-01-03 | 2009-07-09 | Genmab A/S | Monoclonal antibodies against cd32b |
-
2010
- 2010-01-15 EA EA201170940A patent/EA201170940A1/ru unknown
- 2010-01-15 WO PCT/US2010/021123 patent/WO2010083365A1/en not_active Ceased
- 2010-01-15 CA CA2749151A patent/CA2749151A1/en not_active Abandoned
- 2010-01-15 KR KR1020117018826A patent/KR20110111303A/ko not_active Withdrawn
- 2010-01-15 JP JP2011546347A patent/JP2012515217A/ja active Pending
- 2010-01-15 BR BRPI1006829A patent/BRPI1006829A2/pt not_active IP Right Cessation
- 2010-01-15 CN CN2010800123232A patent/CN102355907A/zh active Pending
- 2010-01-15 US US13/144,335 patent/US20110274697A1/en not_active Abandoned
- 2010-01-15 MX MX2011007589A patent/MX2011007589A/es not_active Application Discontinuation
- 2010-01-15 AU AU2010204666A patent/AU2010204666A1/en not_active Abandoned
- 2010-01-15 SG SG2011047107A patent/SG172792A1/en unknown
- 2010-01-15 EP EP10732123A patent/EP2405937A4/en not_active Withdrawn
-
2011
- 2011-06-27 IL IL213794A patent/IL213794A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012515217A5 (https=) | ||
| Long et al. | Dysregulation of glutamate transport enhances treg function that promotes VEGF blockade resistance in glioblastoma | |
| Hutchings et al. | Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma | |
| Durand et al. | Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial | |
| KR20210126652A (ko) | Tno155 및 pd-1 억제제를 포함하는 약제학적 조합물 | |
| JP2015532292A5 (https=) | ||
| Tsai et al. | A multikinase and DNA-PK inhibitor combination immunomodulates melanomas, suppresses tumor progression, and enhances immunotherapies | |
| Iribarren et al. | Anticancer effects of anti-CD47 immunotherapy in vivo | |
| Phillips et al. | Glofitamab step-up dosing induces high response rates in patients (pts) with relapsed or refractory (R/R) mantle cell lymphoma (MCL), most of whom had failed prior Bruton's tyrosine kinase inhibitor (BTKi) therapy | |
| JP2017501155A5 (https=) | ||
| IL278423B1 (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer | |
| RU2018105985A (ru) | Новый подход к лечению рака с применением иммуномодуляции | |
| JP2018503610A5 (https=) | ||
| Richardson et al. | MM-005: a phase 1, multicenter, open-label, dose-escalation study to determine the maximum tolerated dose for the combination of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma | |
| JP2017537927A5 (https=) | ||
| JP2013541587A5 (https=) | ||
| Flinn et al. | Subcutaneous mosunetuzumab is active and has a manageable safety profile in patients with previously untreated, low-tumor burden follicular lymphoma: initial results from the phase II Morningsun study | |
| Hoag et al. | Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review | |
| Iriyama et al. | The efficacy of reduced-dose dasatinib as a subsequent therapy in patients with chronic myeloid leukemia in the chronic phase: the LD-CML study of the Kanto CML Study Group | |
| Gonzalez-Nicolini et al. | Premedication and chemotherapy agents do not impair imgatuzumab (GA201)-mediated antibody-dependent cellular cytotoxicity and combination therapies enhance efficacy | |
| Mahadevan et al. | First-in-human phase I dose escalation study of a humanized anti-CD200 antibody (Samalizumab) in patients with advanced stage B cell chronic lymphocytic leukemia (B-CLL) or multiple myeloma (MM) | |
| Bartlett et al. | Polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for patients with previously untreated diffuse large B-cell lymphoma (DLBCL): preliminary results of a phase Ib dose-escalation | |
| Ludwig et al. | Final results from the phase IIa study of the anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in combination with bortezomib and dexamethasone in patients with multiple myeloma | |
| JP2013543869A5 (https=) | ||
| RU2013127115A (ru) | Комбинированная терапия при в-клеточных лимфомах |